• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series.成年银屑病患者的司库奇尤单抗剂量优化：一项回顾性多中心病例系列研究。
JAAD Case Rep. 2018 Mar 31;4(4):310-313. doi: 10.1016/j.jdcr.2017.11.006. eCollection 2018 May.
2
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.古塞库单抗与司库奇尤单抗治疗中重度银屑病（ECLIPSE）：一项 3 期随机对照临床试验的结果。
Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8.
3
Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.69 例中重度斑块型银屑病患者使用司库奇尤单抗的有效性和安全性：一项回顾性多中心研究。
Dermatol Ther. 2017 Nov;30(6). doi: 10.1111/dth.12550. Epub 2017 Sep 14.
4
Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.司库奇尤单抗改善环孢素 A 应答不足的银屑病患者的症状：评估直接转换的前瞻性研究。
J Dermatol. 2017 Oct;44(10):1105-1111. doi: 10.1111/1346-8138.13911. Epub 2017 May 23.
5
The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.三种银屑病评估工具的可靠性：银屑病面积和严重程度指数、体表面积和医师整体评估。
Adv Clin Exp Med. 2017 Aug;26(5):851-856. doi: 10.17219/acem/69804.
6
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.司库奇尤单抗在清除中重度斑块状银屑病患者皮肤方面优于乌司奴单抗：CLEAR，一项随机对照试验。
J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17.
7
Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.医生全球评估（PGA）和银屑病面积和严重程度指数（PASI）：为什么两者都要？生物制剂治疗中度至重度斑块型银屑病的随机对照试验的系统分析。
J Am Acad Dermatol. 2012 Mar;66(3):369-75. doi: 10.1016/j.jaad.2011.01.022. Epub 2011 Oct 29.
8
Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.在意大利银屑病患者中司库奇尤单抗的有效性和安全性：一项 84 周、多中心、回顾性真实世界研究。
Expert Opin Biol Ther. 2019 Aug;19(8):855-861. doi: 10.1080/14712598.2019.1622678. Epub 2019 May 29.
9
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.司库奇尤单抗在日本中重度斑块状银屑病患者中的疗效和安全性：来自ERASURE（一项随机、安慰剂对照的3期研究）的亚组分析
J Dermatol. 2014 Dec;41(12):1039-46. doi: 10.1111/1346-8138.12668. Epub 2014 Oct 30.
10
Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.在真实环境中使用司库奇尤单抗治疗斑块状银屑病患者：西班牙的一项 52 周、多中心、回顾性研究。
J Dermatolog Treat. 2019 Aug;30(5):424-429. doi: 10.1080/09546634.2018.1528000. Epub 2018 Dec 3.

引用本文的文献

1
Management of Guttate Psoriasis: A Systematic Review.点滴状银屑病的治疗：系统评价。
J Cutan Med Surg. 2024 Nov-Dec;28(6):577-584. doi: 10.1177/12034754241266187. Epub 2024 Jul 30.
2
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.司库奇尤单抗剂量递增治疗中重度斑块状银屑病患者的疗效和安全性：来自 PURE 登记研究的数据。
Arch Dermatol Res. 2024 Jun 8;316(7):362. doi: 10.1007/s00403-024-03122-w.
3
Interleukin-17 Inhibitor Combination Therapies for the Treatment of Psoriasis: A Systematic Review.用于治疗银屑病的白细胞介素-17抑制剂联合疗法：一项系统评价
J Clin Aesthet Dermatol. 2022 Jun;15(6 Suppl 1):S19-S31.
4
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.皮肤科治疗药物监测：优化司库奇尤单抗治疗慢性斑块型银屑病的剂量方法。
Clin Exp Dermatol. 2022 Jul;47(7):1324-1336. doi: 10.1111/ced.15157. Epub 2022 Apr 25.
5
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.比美吉珠单抗治疗中度至重度斑块型银屑病：来自一项 IIa 期、随机、双盲、多中心研究的疗效、安全性、药代动力学、药效学和转录组学。
Br J Dermatol. 2022 Apr;186(4):652-663. doi: 10.1111/bjd.20827. Epub 2021 Dec 27.
6
A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management.比利时关于银屑病治疗目标结局集定义的共识。
J Eur Acad Dermatol Venereol. 2020 Apr;34(4):676-684. doi: 10.1111/jdv.16104. Epub 2020 Jan 2.
7
Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report.在银屑病中联合使用甲氨蝶呤优化司库奇尤单抗治疗：综述与病例报告
Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):17-22. doi: 10.1159/000501994. eCollection 2019 Sep-Dec.

本文引用的文献

1
Secukinumab in plaque psoriasis--results of two phase 3 trials.司库奇尤单抗治疗斑块状银屑病的两项 3 期临床试验结果。
N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
2
Heterogeneity of response to biologic treatment: perspective for psoriasis.生物治疗反应的异质性：银屑病的展望。
J Invest Dermatol. 2014 Jan;134(1):18-23. doi: 10.1038/jid.2013.326. Epub 2013 Aug 6.

Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series.

作者信息

Phung Michelle, Georgakopoulos Jorge R, Ighani Arvin, Giroux Lyne, Yeung Jensen

机构信息

Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.

Schulich School of Medicine and Dentistry, Western University, London, Canada.

出版信息

JAAD Case Rep. 2018 Mar 31;4(4):310-313. doi: 10.1016/j.jdcr.2017.11.006. eCollection 2018 May.

DOI:10.1016/j.jdcr.2017.11.006
PMID:29693056
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5911809/
Abstract
摘要